Stepping out last week as the second biosimilar approved in the U.S., Pfizer Inc.'s Inflectra is decked out in a label, replete with extrapolated indications, that reflects the FDA's most recent guidance. Read More
HONG KONG — A new system developed by Australian scientists for generating induced multipotent stem (iMS) cells could result in stem cell therapies for regenerating any human tissue becoming available in the near future, with clinical trials slated to begin in orthopedic patients as early as next year, if the new technique first proves safe and effective in mice. Read More
HONG KONG – Taking another step to strengthen its presence in the promising Chinese market, South Korea-based Hanmi Science Co. Ltd. (KS:008930) will pour about $200 million into a new plant in the fast growing neighboring market. Read More
NEW DELHI – Taking another step toward international expansion, Indian pharma major Biocon Ltd. has secured its first approval in Japan for its biosimilar insulin glargine. Read More
SHANGHAI – Juno Therapeutics inc., of Seattle, has decided to make its mark in China by partnering with Shanghai-based Wuxi Apptec, a contract research service platform, to build a new company from the ground up, dubbed JW Biotechnology (Shanghai) Ltd. Read More
Nanomaterials Technology Pte Ltd. (NMT), of Singapore, said it inked an agreement with Cao Pharmaceuticals Inc., of Houston, for a worldwide license to develop and market CZ-48, a anti-cancer drug jointly developed by NMT and Cao. CZ-48 is an analogue of camptothecin, a topoisomerase I inhibitor and prodrug that is activated as it enters tumor cells. Read More
